Comparison of T cell depletion strategies from bone marrow, umbilical cord and peripheral blood using five separation systems.
The development of bone marrow transplantation in mismatched or matched unrelated donor situations, the recent use of peripheral blood stem cells for allogeneic transplants, the standardization and respect of good methodology practices highlight the need to evaluate new safe methods of T cell depletion (TCD). We have performed 79 in vitro TCD using five techniques: rabbit complement cytotoxicity, CD2-CD7 immunomagnetic depletion, CD5-CD8 panning system, CD34 positive purging and counterflow centrifugation elutriation (CCE). We analyzed these different approaches with regard to the degree of T and B depletion, recovery of progenitors and NK cells. In our hands, the 5 systems evaluated showed a TCD of between 1.3 and 3 log. The CCE, immunomagnetic, complement and panning methods all give similar a TCD of around 2 log. In contrast, we obtained a TCD of approximately 3 log with CD34 positive purging. The progenitor yield was around 50% regardless of the technique used. However, the degree of B and NK cell depletion was dependent on the method: specific TCD resulted in low BCD (under 0.5 log), whereas CCE or CD34 positive purging gave a BCD of greater than 1 log. Moreover, CD34 positive selection resulted in a virtually complete elimination of NK cells. CCE was the only technique allowing isolation of the small lymphocyte population which can be useful for adoptive therapy. To obtain TCD over three logarithms, double purging techniques are necessary. Because specific roles of T cells subsets in engraftment, graft versus host disease, Epstein Barr virus associated B cell lymphoproliferative disorders and disease relapse have not yet been completely elucidated, new techniques such as CD34 positive purging and double purging methods (positive and negative purging) need to be clinically evaluated, especially with respect to peripheral blood stem cells.
Feugier
P
P
Etablissement de Transfusion Sanguine de Lorraine, Site de Nancy, France.
Thévenin
S
S
Billot
M
M
Serrurier
B
B
Loigerot
C
C
Schooneman
F
F
Janot
C
C
Hervé
P
P
Racadot
E
E
D000818:Animals; D018952:Antigens, CD34 / Q000737:chemistry / Q000276:immunology; D019011:Antigens, CD7 / Q000737:chemistry / Q000276:immunology; D001853:Bone Marrow / Q000737:chemistry / Q000276:immunology; D001854:Bone Marrow Cells; D018801:CD2 Antigens / Q000737:chemistry / Q000276:immunology; D018956:CD5 Antigens / Q000737:chemistry / Q000276:immunology; D016827:CD8 Antigens / Q000737:chemistry / Q000276:immunology; D003165:Complement System Proteins / Q000737:chemistry / Q000276:immunology; D005312:Fetal Blood / Q000737:chemistry / Q000166:cytology* / Q000276:immunology; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000737:chemistry / Q000166:cytology* / Q000276:immunology; D006801:Humans; D018189:Immunomagnetic Separation / Q000706:statistics & numerical data; D007963:Leukocytes, Mononuclear / Q000166:cytology*; D008212:Lymphocyte Depletion / Q000379:methods* / Q000706:statistics & numerical data; D010641:Phenotype; D011817:Rabbits; D013601:T-Lymphocytes / Q000737:chemistry / Q000166:cytology* / Q000276:immunology
D018952:Antigens, CD34; D019011:Antigens, CD7; D018801:CD2 Antigens; D018956:CD5 Antigens; D016827:CD8 Antigens; D003165:Complement System Proteins